Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.69 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.49 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8973342 | 0.92 | MAOB (0.81) | MAOBNPC1RAB9AEGLN1DGAT1 | |
| SCHEMBL14329887 | 0.85 | MAOB (0.71) | MAOBNPC1RAB9AEGLN1DGAT1 | |
| SCHEMBL8396789 | 0.85 | MAOB (0.71) | MAOBNPC1RAB9AEGLN1DGAT1 | |
| SCHEMBL19835607 | 0.85 | MAOB (0.76) | MAOBMALT1NPC1RAB9AEGLN1 | |
| SCHEMBL23417254 | 0.84 | EGLN1 (0.51) | MAOBMALT1NPC1RAB9AEGLN1 | |
| SCHEMBL29262574 | 0.82 | MAOB (0.71) | MAOBNPC1RAB9AEGLN1DGAT1 | |
| SCHEMBL29459609 | 0.82 | MAOB (0.71) | MAOBNPC1RAB9AEGLN1DGAT1 | |
| Lazabemide SCHEMBL20769840 | 0.82 | MAOB (1.00) | MAOBMALT1NPC1RAB9AEGLN1 | |
| Lazabemide SCHEMBL29710899 | 0.82 | MAOB (1.00) | MAOBMALT1NPC1RAB9AEGLN1 | |
| Lazabemide SCHEMBL121998 | 0.82 | MAOB (1.00) | MAOBMALT1NPC1RAB9AEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150191430-A1 | CONJUGATES OF HUPERZINE AND ANALOGS THEREOF | BISCAYNE NEUROTHERAPEUTICS, INC. | 2015-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191430-A1 | CONJUGATES OF HUPERZINE AND ANALOGS THEREOF | HTT, HNMT, GAP43 | MAOB 160/4885MALT1 2663/4885NPC1 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.